Abstract:Background: Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disorder caused by sarcomeric gene variants and associated with left ventricular hypertrophy and diastolic dysfunction. The role of the microtubule network has recently gained interest with the findings that microtubule detyrosination (dTyr-MT) is markedly elevated in heart failure. Acute reduction of dTyr-MT by inhibition of the detyrosinase (VASH [vasohibin]/SVBP [small VASH-binding protein] complex) or activation of the tyrosinase (TTL [tubulin tyrosine ligase]) markedly improved contractility and reduced stiffness in human failing cardiomyocytes and thus posed a new perspective for HCM treatment. In this study, we tested the impact of chronic tubulin tyrosination in an HCM mouse model (Mybpc3 knock-in), in human HCM cardiomyocytes, and in SVBP-deficient human engineered heart tissues (EHTs). Methods: Adeno-associated virus serotype 9-mediated TTL transfer was applied in neonatal wild-type rodents, in 3-week-old knock-in mice, and in HCM human induced pluripotent stem cell-derived cardiomyocytes. Results: We show (1) TTL for 6 weeks dose dependently reduced dTyr-MT and improved contractility without affecting cytosolic calcium transients in wild-type cardiomyocytes; (2) TTL for 12 weeks reduced the abundance of dTyr-MT in the myocardium, improved diastolic filling, compliance, cardiac output, and stroke volume in knock-in mice; (3) TTL for 10 days normalized cell area in HCM human induced pluripotent stem cell-derived cardiomyocytes; (4) TTL overexpression activated transcription of tubulins and other cytoskeleton components but did not significantly impact the proteome in knock-in mice; (5) SVBP-deficient EHTs exhibited reduced dTyr-MT levels, higher force, and faster relaxation than TTL-deficient and wild-type EHTs. RNA sequencing and mass spectrometry analysis revealed distinct enrichment of cardiomyocyte components and pathways in SVBP-deficient versus TTL-deficient EHTs. Conclusions: This study provides the first proof of concept that chronic activation of tubulin tyrosination in HCM mice and in human EHTs improves heart function and holds promise for targeting the nonsarcomeric cytoskeleton in heart disease.

On the Capacity of Tandem Server, Finite Queue, Service Systems

Danicamtiv reduces myosin's working stroke but enhances contraction by activating the thin filament

Danicamtiv affected isometric force and cross-bridge kinetics similarly in skinned myocardial strips from male and female rats

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases

Abstract P439: Harnessing Multiscale Models Of A Dilated Cardiomyopathy Mutation For Precision Medicine

Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor

Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T

[Reverse root canal filling using glass cement. First experiences].

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

1-Deoxynojirimycin Promotes Cardiac Function and Rescues Mitochondrial Cristae in Mitochondrial Hypertrophic Cardiomyopathy.

Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy

Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism

Chronic Activation of Tubulin Tyrosination Improves Heart Function

Mechanistic basis for rescuing hypertrophic cardiomyopathy with myosin regulatory light chain phosphorylation

Neutraceuticals silybin B, resveratrol and epigallocatechin-3 gallate (EGCG) bind to troponin to restore the loss of lusitropy caused by cardiomyopathy mutations in vitro, in vivo, and in silico

In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by TPM1 M8R

Measurement of single-breath carbon monoxide transfer factor (diffusing capacity) during progressive exercise.

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy

Biased Agonism at the Angiotensin Receptor: Blocker and Calcium Sensitizer at the Same Time

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility